Mercy Health Muskegon   Report issue

Academic/Hospital Phase 4
Founded: Muskegon MI United States (1903)

Organization Overview

First Clinical Trial
2019
NCT04141553
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Mercy Health Muskegon

Active Ingredients

Drugs in Phase 4 Trials (1)

diltiazem (cardizem) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atrial Fibrillation (Phase 4)

Atrial Flutter (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 1
  • # of Trial APIs: 1